Your browser is no longer supported. Please, upgrade your browser.
CRSP CRISPR Therapeutics AG monthly Stock Chart
CRISPR Therapeutics AG
Index- P/E- EPS (ttm)-3.25 Insider Own1.30% Shs Outstand70.14M Perf Week11.27%
Market Cap7.77B Forward P/E- EPS next Y-5.28 Insider Trans-35.35% Shs Float60.85M Perf Month28.34%
Income-211.30M PEG- EPS next Q-1.27 Inst Own69.30% Short Float7.71% Perf Quarter34.00%
Sales77.40M P/S100.41 EPS this Y134.10% Inst Trans23.55% Short Ratio5.10 Perf Half Y82.53%
Book/sh19.15 P/B6.35 EPS next Y-5.20% ROA-18.40% Target Price102.63 Perf Year78.46%
Cash/sh21.36 P/C5.69 EPS next 5Y- ROE-20.70% 52W Range32.30 - 111.90 Perf YTD99.57%
Dividend- P/FCF- EPS past 5Y54.00% ROI4.90% 52W High8.62% Beta2.17
Dividend %- Quick Ratio16.50 Sales past 5Y- Gross Margin- 52W Low276.32% ATR5.67
Employees304 Current Ratio16.50 Sales Q/Q-100.00% Oper. Margin- RSI (14)74.92 Volatility4.42% 5.44%
OptionableYes Debt/Eq0.00 EPS Q/Q-154.80% Profit Margin- Rel Volume1.24 Prev Close110.00
ShortableYes LT Debt/Eq0.00 EarningsOct 28 BMO Payout- Avg Volume920.00K Price121.55
Recom2.20 SMA2019.26% SMA5026.44% SMA20063.53% Volume1,124,306 Change10.50%
Oct-23-20Initiated RBC Capital Mkts Sector Perform $110
Oct-05-20Initiated BofA Securities Buy $110
Jul-28-20Reiterated Needham Buy $84 → $105
Jul-14-20Initiated SunTrust Buy $140
Jun-15-20Reiterated Canaccord Genuity Buy $80 → $84
Mar-05-20Initiated Stifel Hold $52
Feb-03-20Downgrade Evercore ISI Outperform → In-line $85 → $52
Nov-19-19Upgrade William Blair Mkt Perform → Outperform
Nov-12-19Upgrade Oppenheimer Perform → Outperform $65
Aug-01-19Initiated Jefferies Buy $64
Jul-26-19Initiated Canaccord Genuity Buy $72
Jun-10-19Initiated ROTH Capital Buy $50
Apr-12-19Initiated Evercore ISI Outperform
Mar-14-19Initiated William Blair Mkt Perform
Jan-28-19Downgrade Goldman Buy → Neutral
Jan-22-19Downgrade Citigroup Neutral → Sell
Nov-30-18Initiated Needham Buy $62
Oct-10-18Initiated Wells Fargo Outperform $65
Oct-10-18Initiated Guggenheim Neutral
Sep-21-18Initiated Raymond James Underperform
Nov-24-20 08:00AM  
Nov-21-20 06:33AM  
Nov-20-20 09:17AM  
Nov-16-20 08:00AM  
Nov-14-20 05:24AM  
Nov-07-20 07:04AM  
Nov-04-20 04:17PM  
Nov-02-20 07:34AM  
Oct-31-20 06:43AM  
Oct-29-20 08:51AM  
Oct-28-20 04:59PM  
Oct-24-20 08:55AM  
Oct-22-20 05:41PM  
Oct-21-20 05:58PM  
Oct-16-20 12:12PM  
Oct-15-20 11:18AM  
Oct-12-20 09:45AM  
Oct-09-20 10:14AM  
Oct-08-20 01:31PM  
Oct-07-20 06:05PM  
Oct-05-20 02:23PM  
Sep-30-20 06:45AM  
Sep-29-20 08:00AM  
Sep-24-20 06:04AM  
Sep-23-20 11:03AM  
Sep-22-20 09:00AM  
Sep-15-20 11:00AM  
Sep-14-20 07:20AM  
Sep-10-20 06:55AM  
Sep-09-20 05:26PM  
Sep-03-20 08:00AM  
Aug-26-20 11:30AM  
Aug-20-20 08:33AM  
Aug-18-20 11:41AM  
Jul-30-20 08:00AM  
Jul-29-20 06:53AM  
Jul-28-20 03:53AM  
Jul-27-20 06:15PM  
Jul-26-20 08:10AM  
Jul-25-20 11:52AM  
Jul-21-20 07:07AM  
Jul-17-20 10:11AM  
Jul-15-20 03:13PM  
Jul-13-20 10:53AM  
Jul-08-20 01:35PM  
Jul-07-20 10:00AM  
Jul-02-20 08:43AM  
Jun-30-20 09:30PM  
Jun-29-20 04:01PM  
Jun-26-20 08:20AM  
Jun-25-20 08:00AM  
Jun-20-20 09:48AM  
Jun-16-20 06:30AM  
Jun-14-20 06:00AM  
Jun-12-20 02:12PM  
Jun-05-20 09:35AM  
Jun-03-20 07:54AM  
Jun-01-20 11:46AM  
May-28-20 11:31AM  
May-26-20 08:30AM  
May-19-20 05:09AM  
May-18-20 06:32PM  
May-16-20 10:00AM  
May-15-20 08:30AM  
May-14-20 09:02AM  
May-12-20 03:40PM  
May-11-20 05:19PM  
May-07-20 08:00AM  
Apr-30-20 06:27AM  
Apr-28-20 07:45PM  
Apr-27-20 12:31PM  
Apr-24-20 11:41AM  
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for serious human diseases. It develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), a gene editing technology that allows for precise directed changes to genomic DNA. It has a portfolio of therapeutic programs in a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It is also developing CTX110, a donor-derived gene-edited allogeneic CAR-T therapy targeting cluster of differentiation 19 positive malignancies. In addition, the company is developing allogeneic CAR-T programs comprising CTX120 targeting B-cell maturation antigen for the treatment of multiple myeloma; and CTX130 for the treatment of solid tumors and hematologic malignancies. Further, it engages in developing regenerative medicine programs in diabetes; and in vivo and other genetic disease programs to treat glycogen storage disease Ia, Duchenne muscular dystrophy, and cystic fibrosis. The company has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Novak RodgerPresidentOct 09Option Exercise14.432,76239,856650,769Oct 13 04:44 PM
Novak RodgerPresidentOct 09Sale100.002,762276,200648,007Oct 13 04:44 PM
Novak RodgerPresidentOct 08Option Exercise14.4322,238320,894670,245Oct 13 04:44 PM
Novak RodgerPresidentOct 08Sale100.0022,2382,223,800648,007Oct 13 04:44 PM
Bolzon Bradley J PhDDirectorSep 18Sale86.873,035263,636518,190Sep 22 08:10 PM
Bolzon Bradley J PhDDirectorSep 16Sale86.988,965779,777521,225Sep 18 04:30 PM
Bolzon Bradley J PhDDirectorSep 14Sale84.891,15598,045530,190Sep 16 08:00 PM
Bolzon Bradley J PhDDirectorSep 10Sale85.3622,8451,949,996531,345Sep 11 09:49 PM
TOMSICEK MICHAEL JOHNChief Financial OfficerSep 01Option Exercise17.7512,000213,00012,410Sep 03 04:46 PM
Novak RodgerPresidentSep 01Option Exercise14.3625,000359,059673,007Sep 03 04:44 PM
Bolzon Bradley J PhDDirectorSep 01Option Exercise25.2360,0001,513,95060,000Sep 03 09:21 PM
Bolzon Bradley J PhDDirectorSep 01Sale92.5160,0005,550,6440Sep 03 09:21 PM
Novak RodgerPresidentSep 01Sale92.6225,0002,315,578648,007Sep 03 04:44 PM
TOMSICEK MICHAEL JOHNChief Financial OfficerSep 01Sale92.2612,0001,107,068410Sep 03 04:46 PM
Novak RodgerPresidentAug 19Option Exercise14.0025,000350,000673,007Aug 21 04:11 PM
Novak RodgerPresidentAug 19Sale100.0025,0002,500,000648,007Aug 21 04:11 PM
TOMSICEK MICHAEL JOHNChief Financial OfficerAug 03Option Exercise17.7512,000213,00012,410Aug 05 04:20 PM
TOMSICEK MICHAEL JOHNChief Financial OfficerAug 03Sale86.7412,0001,040,919410Aug 05 04:20 PM
Novak RodgerPresidentJul 07Option Exercise11.2825,000281,907673,007Jul 09 04:00 PM
Novak RodgerPresidentJul 07Sale90.0025,0002,250,000648,007Jul 09 04:00 PM
Bolzon Bradley J PhDDirectorJul 06Sale82.3920,0001,647,730554,190Jul 08 04:00 PM
Novak RodgerPresidentJul 01Sale80.0050,0004,000,000648,007Jul 06 04:14 PM
Klein Lawrence OttoCBO & COOJun 25Option Exercise12.574,91261,74424,912Jun 26 04:33 PM
Klein Lawrence OttoCBO & COOJun 25Sale75.184,912369,27220,000Jun 26 04:33 PM
Klein Lawrence OttoCBO & COOJun 24Option Exercise8.5865,088558,70758,666Jun 26 04:33 PM
Klein Lawrence OttoCBO & COOJun 24Sale75.9365,0884,942,29220,000Jun 26 04:33 PM
Novak RodgerPresidentJun 23Sale75.0050,0003,750,000698,007Jun 25 04:28 PM
Bolzon Bradley J PhDDirectorJun 23Sale75.3510,000753,453574,190Jun 24 07:02 PM
Ho Tony WExecutive VP, Head of R&DJun 23Sale75.206,929521,06133,747Jun 24 05:58 PM
Ho Tony WExecutive VP, Head of R&DJun 22Sale70.1422916,06240,676Jun 24 05:58 PM
Bolzon Bradley J PhDDirectorJun 22Sale72.5110,000725,069584,190Jun 24 07:02 PM
Kulkarni SamarthChief Executive OfficerJun 01Option Exercise1.8117,27531,268188,801Jun 03 05:32 PM
Kulkarni SamarthChief Executive OfficerJun 01Sale64.6817,2751,117,266171,526Jun 03 05:32 PM
Ho Tony WExecutive VP, Head of R&DMay 26Sale70.146,100427,85440,905May 27 04:32 PM
Novak RodgerPresidentMay 26Sale70.2736,6162,573,006748,007May 27 04:34 PM
Novak RodgerPresidentMay 22Sale70.0113,384937,014784,623May 27 04:34 PM
Ho Tony WExecutive VP, Head of R&DMay 22Sale70.0560042,03047,005May 27 04:32 PM
Kulkarni SamarthChief Executive OfficerMay 20Option Exercise1.8110,69319,354182,219May 21 04:35 PM
Kulkarni SamarthChief Executive OfficerMay 20Sale65.2810,693698,039171,526May 21 04:35 PM
Kulkarni SamarthChief Executive OfficerMay 19Option Exercise1.814,3077,796175,833May 21 04:35 PM
Novak RodgerPresidentMay 19Sale65.0050,0003,250,000798,007May 21 04:37 PM
Kulkarni SamarthChief Executive OfficerMay 19Sale65.164,307280,644171,526May 21 04:35 PM
Klein Lawrence OttoCBO & COOMay 11Option Exercise5.8625,000146,50045,000May 13 04:38 PM
Klein Lawrence OttoCBO & COOMay 11Sale60.4025,0001,509,97120,000May 13 04:38 PM
Kulkarni SamarthChief Executive OfficerDec 16Option Exercise1.818,00014,480172,320Dec 18 04:05 PM